Chlorprothixene

Quick links to important sections

Chlorprothixene

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Chlorprothixene

Property Description
Active ingredient Chlorprothixene
Form Tablets and solution for injection
Pharmacological Class Typical Antipsychotic (Neuroleptic)
Chemical Group Thioxanthene Derivative
Origin Synthetic Compound

What Type of Medicine is Chlorprothixene?

Chlorprothixene is a medication classified as a typical antipsychotic, or neuroleptic, synthesized primarily for stabilizing severe disturbances in thought and emotional activity. The substance is a synthetic compound that belongs to the thioxanthene derivatives chemical class, representing an established category of psychotropic agents. This classification reflects its recognized pharmacological role in managing severe mental distress. The drug's fundamental function involves acting as a dopamine receptor antagonist, meaning it works by modulating the activity of dopamine, a crucial neurotransmitter associated with perception and mood stabilization.


Composition, Forms, and General Purpose

The drug is a single-ingredient product, deriving its therapeutic effect entirely from the active substance, Chlorprothixene, without combination with other pharmacologically active agents. It is prepared for patient use in two key preparations: film-coated tablets for oral administration and a clear solution for injection administered via the intramuscular route. This dual availability is intended for flexible treatment strategies. The general purpose of administering this compound is to reduce states of extreme mental and emotional over-excitement, aiming to achieve behavioral and cognitive equilibrium.


The Distinctive Sedative Action of Chlorprothixene

Chlorprothixene is particularly known for its potent and immediate sedative properties, a distinguishing feature within its pharmacological class, and is often regarded as a low-potency agent. While its primary role is dopamine antagonism, the medication also shows strong affinity for other receptors, notably H1 histamine and alpha1 adrenergic receptors. This specific multireceptor action is responsible for the pronounced calming and anxiolytic effect observed upon administration. This attribute is recognized for its ability to swiftly quell agitation, differentiating its use from less-sedating antipsychotics that may be chosen when immediate calmness is the primary goal.

What side effects are possible with Chlorprothixene?

Possible Side Effects and Safety Information

The officially documented safety profile for Chlorprothixene is organized by the frequency and physiological system affected, providing a descriptive overview of possible adverse reactions as specified in regulatory labeling. The most Very Common documented effects include somnolence (drowsiness), dizziness, dry mouth, and increased salivary secretion, which are often most notable at the beginning of the treatment.


Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized based on the likelihood of occurrence:

  • Common effects (ge 1/100 to < 1/10) include tachycardia, headache, constipation, blurred vision due to accommodation disorder, increased appetite, and weight gain. Movement disorders such as dystonia are also listed in this category.
  • Uncommon effects (ge 1/1,000 to < 1/100) include vomiting, urinary retention, rash, and movement-related effects like akathisia and Parkinsonism. Tardive dyskinesia, an uncommon effect, is associated primarily with long-term exposure.

Serious Safety Considerations

The label documents specific serious reactions and safety constraints. Rare (ge 1/10,000 to < 1/1,000) serious events include QT interval prolongation on the ECG and severe reductions in blood cell counts (e.g., agranulocytosis). Neuroleptic Malignant Syndrome (NMS), a potentially life-threatening reaction, is classified as Very Rare.

Specific regulatory constraints exist for certain groups. Use is restricted in patients with severe central nervous system depression or certain pre-existing significant cardiovascular disorders. Furthermore, an increased risk of death is documented when this medication is used in older adults with dementia-related psychosis.

Overdose and Emergency Response

Overdose and when to seek help

Category Official Regulatory Documentation
Documented overdose presentations Profound CNS depression (somnolence, confusion, coma), convulsions, severe hypotension, and tachycardia.
Physiological systems affected Central Nervous System (CNS), Cardiovascular System, and Autonomic Nervous System.
Population-specific overdose notes Elderly patients are particularly sensitive to anticholinergic side effects and face an increased risk of death (associated with dementia-related psychosis) when exposed to antipsychotics.
When immediate medical help is required Seek immediate medical attention for any suspected overdose; contact emergency services for seizures, profound unresponsiveness, or severe difficulty breathing.

Resulting Overdose Structure

Official Overdose Statements:

  • Overdose presents a potential for life-threatening outcomes, including circulatory collapse, malignant ventricular arrhythmias, and QTc interval prolongation.
  • The potential for Neuroleptic Malignant Syndrome (NMS) is a documented systemic syndrome risk for neuroleptic exposure.
  • No specific antidote is known; management requires intensive symptomatic and supportive treatment, including continuous ECG monitoring and specific vasopressor agents for severe hypotension.

Connection to the overall overdose profile (2–4 sentences): The official documentation defines the overdose profile by linking high exposure to critical, life-threatening cardiovascular instability and profound CNS toxicity. Due to this documented severity and the absence of a specific antidote, regulatory guidance mandates that users seek immediate medical attention for all suspected cases, which necessitates specialized, intensive supportive care, including continuous cardiac monitoring.

Therapeutic Uses of Chlorprothixene

What Chlorprothixene Treats: Main Uses and Benefits

Chlorprothixene may be used in situations involving certain distressing symptoms, such as severe, acute psychiatric manifestations and certain secondary manifestations. It is commonly applied in clinical settings that involve acute or unstable symptom patterns, providing supportive symptom management.

The medication is relevant across domains where additional symptomatic support is needed, particularly for psychotic disorders, including schizophrenia and acute manic episodes in bipolar disorder. It helps address symptom clusters that may become intense or disruptive, such as severe agitation, hallucinations, and disorganized thinking. The medication is commonly used to help with short-term management of these disruptive, episodic manifestations.

“The medication is applied to moderate challenging symptomatic presentations and contribute to supportive relief during acute phases.”


Key Therapeutic Areas

Chlorprothixene may assist with easing acute psychotic manifestations and managing severe behavioral agitation. Beyond these primary uses, it is also applied to ease challenging symptoms like insomnia (sleep disruption) and severe nausea or vomiting. This supportive benefit may be relevant for easing symptoms related to heightened physiological activity that escalate temporarily. This supports the patient by helping ease the overall symptom burden and supporting general well-being during symptomatic phases.

Quick Fact: Relief for Acute Agitation Chlorprothixene is often applied during phases of increased distress or discomfort to help manage restlessness and tension when symptoms create noticeable functional strain.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Chlorprothixene

Chlorprothixene use is defined by a series of contraindications and restrictions documented in official regulatory labeling. The medicine must not be used by patients who are in comatose states, experiencing circulatory collapse, or who have known hypersensitivity to the drug or related compounds.

Usage is absolutely contraindicated in patients with specific cardiovascular issues, including clinically significant disorders like severe bradycardia (heart rate below 50 beats per minute), uncompensated heart failure, recent acute myocardial infarction, or congenital/acquired QT interval prolongation. It is also forbidden for patients with uncorrected hypokalaemia or hypomagnesaemia or those taking other medications known to significantly prolong the QT interval.

Special Populations and Restrictions

Population Status Eligibility Classification Restriction Basis
Children & Adolescents (<18) Not Recommended Insufficient data on safety and efficacy.
Elderly Patients Restricted/Caution Increased sensitivity; requires particularly low initial doses.
Pregnancy/Lactation Not Recommended Safety not established in pregnancy; excretion into breast milk.
Comorbidities Conditional Use Caution required for Parkinson disease, hyperthyreosis, pheochromocytoma, or conditions causing urinary retention/ileus.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This information describes documented interactions with other substances, based strictly on official regulatory labeling.

Potential Interaction Categories

Interaction Type Interacting Substances/Classes Constraint or Risk
Cardiovascular Effects Drugs that significantly prolong the QT interval (e.g., certain antiarrhythmics, other antipsychotics) Co-administration is contraindicated due to increased risk of serious heart rhythm disturbances. Avoid drugs that cause hypokalaemia (e.g., thiazide diuretics), which can exacerbate the risk.
Central Nervous System (CNS) Effects CNS depressants (e.g., alcohol, barbiturates, benzodiazepines) Concurrent use may result in an enhanced sedative effect and increased CNS depression.
Metabolic/Exposure Effects Potent inhibitors of Cytochrome P450 2D6 (CYP2D6) (e.g., fluoxetine, paroxetine) Co-administration may increase the plasma level of Chlorprothixene, potentially leading to increased effects.
Pharmacodynamic Effects Anticholinergics, Levodopa, Antihypertensives (especially guanethidine) Effects of anticholinergics may be enhanced. The effects of levodopa and adrenergic drugs may be reduced. The antihypertensive effect of guanethidine is reduced.

Required Precautions

Due to the additive risk of neurotoxicity, caution is required during concomitant treatment with Lithium. Concomitant use with other antipsychotics should generally be avoided due to the potential for mutual inhibition of metabolism and additive adverse effects.

Mechanism of Action

Chlorprothixene's action is defined by its ability to engage multiple molecular targets simultaneously, modulating activity within central and peripheral regulatory systems via multi-receptor antagonism. The primary mechanism involves the antagonism of D2 dopamine receptors and 5-HT 2A serotonin receptors. By occupying these binding sites, the drug modifies postsynaptic signaling sequences, altering activity levels in the affected brain regions.

Simultaneously, the drug acts as a competitive antagonist at histamine H1 receptors and muscarinic acetylcholine receptors. This antagonism interferes with the histaminergic system, which regulates physiological arousal, mediating a change that results in generalized CNS depression and reduced physiological excitability. Furthermore, the drug engages in alpha1-adrenergic receptor antagonism, primarily affecting the peripheral autonomic nervous system, modifying molecular steps that influence vascular tone and systemic physiological responses.

Dosage and Administration Information

How to Use Chlorprothixene

Chlorprothixene is administered according to a structured protocol, with administration available via two approved routes: oral (using film-coated tablets) and intramuscular (IM) injection (using a solution). The injectable form is typically reserved for acute clinical settings.

General Dosing Protocol

Treatment begins with a low initial dose that is then increased gradually through titration. A common adult starting dose may be as low as 15 mg to 30 mg daily. The dose is adjusted toward a total daily maintenance range that typically falls between 100 mg and 200 mg in the treatment of psychoses, though the theoretical maximum dose is higher.

Frequency and Administration Context

The total daily dose is commonly administered in divided doses. The scheduling may involve concentrating a larger portion of the dose at bedtime, a pattern established to leverage the medicine’s prominent sedative properties. For patients receiving 90 mg daily or more, particularly during the initial dose-finding phase, management often occurs within a hospitalized setting.

Population-Specific Use

Dose adjustments are specified for certain patient groups. Older adults (over 60 years) require a particularly low initial and maintenance dose, often reduced to one-half or one-third of the standard adult regimen, with slow dose increases. Chlorprothixene is not recommended for use in children and adolescents due to insufficient data on efficacy and safety.

Cessation of Treatment

If the medication is to be discontinued, the dose is decreased steadily over a period of time rather than being stopped abruptly.

Recent Clinical Evidence

Evidence from Studies for Psychotic Disorders and Schizophrenia

Research for Chlorprothixene was evaluated in trials exploring conditions characterized by fluctuating or episodic manifestations, such as schizophrenia and related psychotic disorders. This evidence includes historical Randomized Controlled Trials (RCTs) where the compound was studied for exploring how symptoms are measured and compared to a placebo. These trials research examined core psychotic symptoms and overall global status over short time intervals.

Findings describe patterns observed in studies that contribute to the broader evidence landscape for this chemical class. Certainty remains low for some aspects because the foundational data is limited and comes from trials conducted decades ago. Comparative evidence against contemporary treatments is lacking.

Studies Assessing Acute Symptom Change

Studies focusing on acute symptoms were conducted during periods of increased symptom activity. These trials research examined short-term symptom changes and tracked the immediate profile of the compound on outcomes capturing phases of heightened symptom activity. The findings from these acute studies contribute to understanding symptom patterns in populations experiencing unstable symptoms.


Research on Managing Acute Agitation and Excitement

The compound was studied for use in managing conditions associated with acute or disruptive episodes, specifically severe psychomotor agitation. Evidence relies on a small number of older, short-term RCTs that studies explored the effects of the injectable solution, measuring the speed of observable calming effects. This research provides context but not individual predictions regarding the time needed for change. The data are still emerging from modern comparisons, and subgroup findings are uncertain.


Evidence in Specific Populations and Long-Term Outcomes

Research has explored long-term outcomes used in observational settings evaluating daily-life functioning. While studies monitor outcomes linked to the prevention of re-exacerbation, follow-up durations were limited. The long-term effects are not fully established by prospective, controlled trials. Additionally, the compound was observed in large-scale nationwide prospective cohort studies, but these primarily research examined long-term safety signals rather than initial efficacy for supportive uses like sedation.


What Remains Uncertain and Gaps in the Research

The overall evidence landscape has several gaps where certainty remains low. The evidence quality varies across studies for the primary indications, as much of the core evidence is historical and sample sizes were modest in many initial trials. There is limited information for long-term outcomes tracking functional measures, and the data for older adults and specific subgroups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Chlorprothixene (FAQ)


Q: What is Chlorprothixene used for, besides what my doctor said?

According to the official product information, Chlorprothixene is indicated for treating certain psychotic disorders, including those associated with schizophrenia. It is also used in the management of acute mania in bipolar disorder and for stabilizing states of agitation and anxiety.


Q: Is Chlorprothixene considered a sleeping pill?

Regulatory documents primarily classify Chlorprothixene as a typical antipsychotic medication. However, it is well-recognized for its strong sedative properties, which is a distinguishing feature. Because of this effect, it may be used as a treatment component to help address insomnia.


Q: Why do some people call Chlorprothixene an 'old-school' medication?

Chlorprothixene is a typical antipsychotic drug, meaning it belongs to the first generation of medications in this class. Since these compounds have been in use for several decades, the drug may be neutrally referred to in this way to reflect its position as an established, older treatment option.


Q: How does Chlorprothixene relate to other common medications for similar issues?

Official reviews describe Chlorprothixene as having low potency in its class but with a distinct, strong sedative effect. This sedative property is a key feature distinguishing it from some other medications. Its action is also associated with a higher risk of certain effects, such as dry mouth and low blood pressure, compared to newer agents.


Q: Is Chlorprothixene the same type of drug as medications ending in '-pine' or '-done'?

No, these are generally different classifications. Chlorprothixene is a typical antipsychotic (first-generation) that belongs to a chemical group called the thioxanthene derivatives. Medications with common suffixes like '-pine' or '-done' are usually categorized as atypical (second-generation) antipsychotics.


Q: Can Chlorprothixene be described as an antidepressant?

Official product information confirms that Chlorprothixene is primarily classified as an antipsychotic medication. Although its use is documented in the treatment of agitated depressions, an intrinsic antidepressant effect is not a primary feature of its regulatory classification.


Q: How quickly does Chlorprothixene typically start to have an effect?

The sedative effect of the medication may be observed relatively soon after a dose is taken. However, regulatory information indicates that the full antipsychotic effect—the stabilization of the primary condition—develops more gradually over a longer period of time.


Q: How long do the effects of Chlorprothixene last after taking a dose?

Pharmacological data indicates that Chlorprothixene has an elimination half-life typically ranging from 8 to 12 hours. This figure is used to describe the rate at which the body processes and clears the substance from the system.


Q: Can Chlorprothixene affect my heart rate or blood pressure?

Yes, official safety documentation notes that Chlorprothixene can influence the cardiovascular system. Documented side effects include tachycardia (a rapid heart rate) and substantial hypotension (low blood pressure), especially when moving from a sitting or lying position to standing.


Q: What is the risk of dependence or addiction with Chlorprothixene?

Abruptly stopping the medication is linked to the potential development of withdrawal symptoms, such as nausea, sweating, agitation, and insomnia. Because of this risk, official procedures require the dosage to be decreased gradually when discontinuing treatment.


Q: Are there any common over-the-counter medications that interact with Chlorprothixene?

Regulatory warnings note an increased risk of severe sedation and central nervous system (CNS) depression if the drug is combined with other CNS depressants. This category can include certain active ingredients found in some over-the-counter medications for colds, allergies, or sleep assistance.


Q: Are there any specific supplements or herbal products that should be avoided with Chlorprothixene?

Products known to interfere with the liver's enzyme systems may affect how the body processes Chlorprothixene. For instance, the herbal supplement St. John's Wort is noted to potentially interact with the drug’s metabolism, which may reduce its overall effectiveness.


Q: Is it necessary to have routine blood tests while using Chlorprothixene?

Yes, standard practice requires ongoing routine monitoring due to the potential for certain adverse effects. This monitoring includes regular assessment of blood cell counts, tests of liver and kidney function, and checking heart activity via an electrocardiogram (ECG).


Q: What is the research evidence for Chlorprothixene's use in managing anxiety?

Official regulatory information indicates that Chlorprothixene is used in the treatment of non-psychotic agitation and anxiety. Its mechanism involves acting on certain brain receptors (specifically 5-HT2 antagonism), which is understood to be associated with producing anxiolytic (anxiety-reducing) effects.


Q: What is the 'thioxanthene' class of medications?

Thioxanthenes are a specific chemical class of compounds to which Chlorprothixene belongs. They are characterized as tricyclic derivatives and represent a category of established, first-generation (typical) antipsychotic drugs.


Q: What are the general expectations for a person using Chlorprothixene for their condition?

The general expectation for this type of medication is to achieve control and stabilization of the symptoms associated with the underlying condition. The medication is not presented in official documents as a cure for the condition.


Q: How long does the initial drowsiness from Chlorprothixene usually last?

Official information states that the highest degree of drowsiness (somnolence) is most pronounced when treatment is first initiated. This effect is generally expected to diminish over the first few days as the person's system adjusts to the medication.


Q: Can taking Chlorprothixene affect one's ability to drive?

Due to the very common side effects of drowsiness and dizziness, the drug is known to influence the ability to drive and operate machinery. Official warnings advise caution for driving or operating machinery until the effects of the medication are known.


Q: Does Chlorprothixene affect cholesterol levels?

The use of this medication is associated with potential changes in metabolism, which can include weight gain. Because of this, standard monitoring practice includes routine checks of a complete lipid panel, which measures levels like cholesterol.


Q: What are the restrictions on using Chlorprothixene for people with liver issues?

Because Chlorprothixene is primarily processed in the liver (hepatic metabolism), regulatory guidance requires that patients undergo regular liver function tests as part of routine monitoring throughout the course of treatment.


Q: What are the restrictions on using Chlorprothixene for people with kidney issues?

The medication is partially eliminated from the body through the urine. Due to this process, established monitoring practices require periodic assessments of kidney function tests, such as measuring urea and electrolytes.


Q: Is Chlorprothixene available without a prescription in any countries?

Official regulatory information from countries where the drug is authorized confirms that Chlorprothixene is consistently classified as a prescription-only medicine. It is not available for purchase over the counter.


Q: What is the active ingredient in the medication known by the brand name 'Taractan'?

Regulatory and historical drug listings confirm that the active substance in the medication known by the brand name Taractan is Chlorprothixene.


Q: Can Chlorprothixene affect body temperature regulation?

Yes, this medication may potentially disrupt the body's mechanisms for regulating temperature. This is an effect associated with the serious, although very rare, adverse reaction known as Neuroleptic Malignant Syndrome (NMS).


Q: What are the common reasons a doctor might choose Chlorprothixene over a newer drug?

Official reviews highlight that Chlorprothixene is often considered an inexpensive and readily available treatment option. It is particularly valued in clinical settings for its potent and immediate sedative effect, which may be needed for the quick stabilization of agitation.


Q: Is there a required timeframe for research monitoring when using Chlorprothixene?

Although monitoring is ongoing throughout treatment, established guidelines often recommend a comprehensive re-evaluation of metabolic parameters, including blood tests, after the first 4 to 6 weeks of starting the medication, followed by periodic checks thereafter.


Q: What does official guidance say about Chlorprothixene and sun exposure?

Official guidance advises that caution should be exercised regarding direct sun exposure during treatment. The medication is associated with a potential for photosensitivity, which means the skin may experience an exaggerated or severe sunburn reaction when exposed to sunlight.

How should Chlorprothixene be stored and disposed of?

How to Store and Dispose of Chlorprothixene?

The official storage and disposal guidelines for Chlorprothixene are defined by strict regulatory parameters to maintain product integrity and safety.

Storage and Handling Requirements
Temperature and Environment Must be stored in a cool area and protected from direct sunlight and moisture.
Container Security The product container must be kept tightly sealed and stored locked up (P405 Precautionary Statement) to restrict access.
Stability Context The substance is considered sensitive to light and air, making adherence to container and light protection rules necessary for chemical stability.
Child Safety Mandatory storage instructions require keeping the medicine locked up to prevent accidental access by children.

Disposal Requirements

Official disposal is governed by environmental and waste management regulations. Unused or expired medicine must be disposed of by following local and country regulations, typically involving an approved waste disposal plant (P501 Precautionary Statement). The product must not be released to the environment, including into sewers, drains, or water courses (P273 Precautionary Statement).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Chlorprothixene found in:

A-Z Index: